

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.



Date: 14th November, 2025

**To,
National Stock Exchange of India Limited
Mumbai**

Scrip Code: ARVEE

ISIN: INE006Z01016

Sub: Outcome of Board Meeting held on 14th November, 2025

Pursuant to our Board Meeting intimation letter dated 4th November, 2025 and revised intimation letter dated 7th November, 2025 intimated to the exchange on 7th November, 2025, the Board of Directors in their meeting held today on 14th November, 2025 have inter-alia amongst others approved the following items:

1. Approve and take on record the unaudited financial results of the Company as per Indian Accounting Standards (INDAS) for the half year ended and period ended on 30th September, 2025 including Cash flow Statement for the period ended on 30th September, 2025.
2. Limited Review Report for the period ended on 30th September, 2025
3. Statement of Related Party Transactions


The Board Meeting started at 15:00 Hours and concluded at 16:30 Hours.

Kindly take the above information on record.

Thanking You,

For, Arvee Laboratories (India) Limited

**CHAIRMAN CUM MANAGING DIRECTOR
SHALIN SUDHAKARBHAI PATEL
DIN: 01779902**



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.

**ARVEE LABORATORIES (INDIA) LIMITED****CIN: L24231GJ2012PLC068778****Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,****Iskcon Bopal Road, Ambli, Ahmedabad - 380058****Tel : +91 – 2717-430479 || +91 – 2717-410819****Website : www.arveelabs.com; Email ID : shalin.patel@arveelabs.com****STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER, 2025**

(₹ in Lakhs)

Particulars	As at 30/09/2025	As at 31/03/2025
	Unaudited	Audited
A. ASSETS		
1. Non-current assets		
(a)Property Plant and Equipment	1,524.87	1,527.04
(b)Capital Work-in-Progress	80.57	72.51
(c)Other Intangible assets	0.23	0.23
(d)Financial Assets		
(i)Investments	-	-
(ii)Loans	-	-
(iii)Others Financial Assets	25.29	25.43
(e)Deferred tax assets (Net)	-	-
(f)Non-current Assets (Net)	-	-
(g)Other Non-current assets	18.19	10.92
Sub - Total - Non Current Assets	1,649.14	1,636.12
2. Current assets		
(a)Inventories	1,148.43	455.43
(b)Financial Assets		
(i)Investments	-	-
(ii)Trade receivables		
Billed	241.35	839.77
Unbilled	-	-
(iii)Cash and cash equivalents	93.19	21.10
(iv)Other Bank Balances	596.04	576.36
(v)Others Financial Assets	-	-
(c)Current assets (net)		-
(d)Other current assets	329.93	287.04
Sub - Total - Current Assets	2,408.93	2,179.71
TOTAL - ASSETS	4,058.08	3,815.83



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.



B. EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	1,102.00	1,102.00
(b) Other Equity	2,042.06	2,024.13
Sub - Total - Equity	3,144.06	3,126.13
2. LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	103.44	103.33
(ii) Others Financial Liabilities	-	-
(b) Other non - current liabilities	28.50	29.00
(c) Provisions	-	-
(d) Deferred tax liabilities (Net)	98.20	98.20
Sub - Total - Non - Current Liabilities	230.14	230.53
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	524.05	327.28
Total outstanding due of		
(A) Micro enterprises and small enterprises	33.33	41.15
(B) Creditors other than micro enterprises and small enterprises	490.72	286.13
(iii) Other Financial Liabilities	-	-
(b) Other current liabilities	26.32	30.55
(c) Provisions	133.51	101.33
(d) Current Tax Liabilities (Net)	-	-
Sub Total - Current Liabilities	683.88	459.16
TOTAL EQUITY AND LIABILITIES	4,058.08	3,815.83

For and on behalf of Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL
CHAIRMAN CUM MANAGING DIRECTOR
DIN: 01779902



Date: November 14, 2025

Place: Ahmedabad

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.

**ARVEE LABORATORIES (INDIA) LIMITED****CIN: L24231GJ2012PLC068778****Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,
Iskcon Bopal Road, Ambli, Ahmedabad - 380058****Tel : +91 – 2717-430479 || +91 – 2717-410819; Website : www.arveelabs.com; Email ID : compliance@arveelabs.com****STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON SEPTEMBER 30, 2025****(₹ in Lakhs, except per share data)**

Sr. No.	Particulars	Quarter ended			Half Year Ended		Year ended
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Revenue from Operations	345.05	748.00	1,252.61	1,093.05	2,312.83	3,848.72
2	Other Income	22.96	16.87	15.57	39.83	26.21	65.73
3	Total Revenue (1+2)	368.01	764.87	1,268.18	1,132.88	2,339.04	3,914.45
4	Expenses						
	Cost of material consumed	396.12	548.27	572.64	944.40	1,003.46	1,887.29
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(383.80)	(206.34)	126.94	(590.14)	310.15	180.74
	Employee benefit Expenses	65.55	167.59	111.66	233.13	218.05	449.47
	Finance Costs	4.38	4.33	4.76	8.72	12.54	24.87
	Depreciation and amortisation expenses	30.29	29.41	29.88	59.70	60.55	114.88
	Other expenses	254.44	204.19	291.16	458.62	477.26	970.10
	Total Expenses (4)	366.98	747.45	1,137.04	1,114.43	2,082.00	3,627.36
5	Profit / (Loss) before exceptional items and tax (1-4)	1.03	17.42	131.14	18.46	257.04	287.09
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5-6)	1.03	17.42	131.14	18.46	257.04	287.09
8	Tax expense						
	Current Tax	0.02	0.51	33.00	0.53	64.69	58.40
	Deferred Tax	-	-	-	-	-	13.96
9	Profit / (Loss) for the period from continuing operations (7-8)	1.01	16.91	98.13	17.93	192.34	214.74
10	Profit / (Loss) from discontinued operations	-	-	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-	-	-
12	Profit / (Loss) from discontinued operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit / (Loss) for the period (9+12)	1.01	16.91	98.13	17.93	192.34	214.74
14	Other Comprehensive Income						
	a. Items that will not be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
	b. Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
15	Total Comprehensive Income for the period (13+14)	1.01	16.91	98.13	17.93	192.34	214.74
	Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.



16	Earnings per equity share (for continuing operation)						
	Basic	0.01	0.15	0.89	0.16	1.75	1.95
	Diluted	0.01	0.15	0.89	0.16	1.75	1.95
17	Earnings per equity share (for discontinued operation)						
	Basic	-	-	-	-	-	-
	Diluted	-	-	-	-	-	-
18	Earnings per equity share (for continuing & discontinued operation)						
	Basic	0.01	0.15	0.89	0.16	1.75	1.95
	Diluted	0.01	0.15	0.89	0.16	1.75	1.95
	Paid-up equity share capital (Face value of ₹ 10 each)	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00
	Other Equity excluding Revaluation Reserve	2,042.06	2,041.05	2,001.75	2,042.06	2,001.75	2,024.13

Notes :

- The aforesaid Financial Results for the quarter ended September 30, 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on Friday, November 14, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The aforesaid Financial Results for the quarter ended September 30, 2025 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which is considered to be the only reportable segment by the management.
- Figures for the quarter ended on 30th September, 2025 and Year ended on 31st March, 2025 the Company has adopted Ind AS. The adoption of the standard did not have any material impact to the financial statements of the Company.
- Consolidated financial Results are not applicable.
- The figures for the corresponding Previous period have been restated / regrouped wherever necessary, to make them comparable.

For and on behalf of Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL
CHAIRMAN CUM MANAGING DIRECTOR
DIN: 01779902

Date: November 14, 2025

Place: Ahmedabad



ARVEE LABORATORIES (INDIA) LIMITED

CIN: L24231GJ2012PLC068778

Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,
Iskcon Bopal Road, Ambli, Ahmedabad - 380058

Tel : +91 – 2717-430479 || +91 – 2717-410819; Website : www.arveelabs.com; Email ID : compliance@arveelabs.com

Statement of Cash Flows for the year ended 30th September, 2025

(₹ in Lakhs, except per share data)

Particulars	for the Half year ended 30th September, 2025	for the year ended 31st March, 2025	for the Half year ended 30th September, 2024
	(Un-Audited)	Audited	(Un-Audited)
A. Cash Flow from Operating Activities			
Net Profit Before Tax	18.46	287.08	257.04
Adjustment for :			
Depreciation	59.70	114.88	60.55
Amortisation	-	0.13	0.06
Finance Costs recognised in Statement of Profit and Loss	8.69	24.68	12.54
Finance Costs recognised in Statement of Profit and Loss relating to Investing Activity	0.03	0.04	0.02
Interest Income recognised in Statement of Profit and Loss	(23.69)	(40.31)	(18.36)
Loss /(Gain) on Sale of Investments	(6.72)	(13.46)	(0.81)
Loss /(Gain) on Disposal of Property, Plant & Equipment	-	0.09	0.11
Operating Profit before Working capital Changes	56.47	373.14	311.15
Adjustment for (Increase) / Decrease in Working Capital :			
Inventories	(693.00)	184.09	252.74
Trade Receivables	598.42	(228.60)	(372.43)
Loans and Advances	(7.14)	(22.18)	27.79
Other Current Assets	(43.40)	(2.98)	52.11
Trade Payables and Provisions	228.44	(311.43)	(104.37)
Other Current Liability	(4.23)	4.27	(3.74)
Cash generated from Operations	135.57	-3.68	163.25
Direct Taxes Paid (Net)		-	-
Net Cash from Operating Activities	135.57	-3.68	163.25
B. Cash Flow from Investing Activities :			
Purchase of Propoerty, Plant and Equipments, other intangible Assets & Capital Work-in-progress	(65.61)	(185.36)	(104.66)
Proceeds from Propoerty, Plant and Equipments, other intangible Assets & Capital Work-in-progress	-	0.12	0.12
Purchase of Investments	(550.00)	(857.36)	(489.14)
Preceeds From Sale of Investment	556.69	863.42	275.40
Profit on sale of Investment	-	-	-
Interest received	4.01	40.31	18.36
Net Cash used in Investing Activities	(54.91)	(138.87)	(299.92)
C. Cash Flow from Financing Activities :			
Share Capital Issued		-	-
Security Premium Received		-	-
Preliminary Expenses Incurred		-	-
Borrowings	0.11	3.33	-
Finance Cost Paid	(8.69)	(24.68)	(12.54)
Net Cash Generated from/(used in) Financing Activities	(8.58)	(21.35)	(12.54)
Net increase in Cash and Cash Equivalents (A+B+C)	72.08	(163.90)	(149.21)
D. Cash and Cash Equivalents as at beginning of period	21.10	185.01	185.01
Cash and Cash Equivalents as at the end of the period (A+B+C+D)	93.18	21.11	35.80
Cash and Cash Equivalents as at end of the period	93.18	21.11	35.80

For and on behalf of Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITEDSHALIN SUDHAKARBHAI PATEL
CHAIRMAN CUM MANAGING DIRECTOR
DIN: 01779902

Date: November 14, 2025

Place: Ahmedabad



INDEPENDENT AUDITOR'S REPORT

To,
THE BOARD OF DIRECTORS OF
ARVEE LABORATORIES (INDIA) LIMITED
AHMEDABAD

Independent Auditors Review Report on Standalone Unaudited Financial Results of the Arvee Laboratories (India) Limited pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of ARVEE LABORATORIES (INDIA) LIMITED ("the Company") for the quarter ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Nirav Patel & Associates
Chartered Accountants
(Firm's Registration No. 129824W)

CA Nirav Patel
Partner
(Membership No. 132409)
UDIN: 25132409BMLKUB3761



Place: Ahmedabad
Date: November 14, 2025